CSBR
Income statement / Annual
Last year (2024), Champions Oncology, Inc.'s total revenue was $50.16 M,
a decrease of 6.90% from the previous year.
In 2024, Champions Oncology, Inc.'s net income was -$7.28 M.
See Champions Oncology, Inc.’s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
| Period Ended |
04/30/2024 |
04/30/2023 |
04/30/2022 |
04/30/2021 |
04/30/2020 |
04/30/2019 |
04/30/2018 |
04/30/2017 |
04/30/2016 |
04/30/2015 |
| Operating Revenue |
$50.16 M
|
$53.87 M
|
$49.11 M
|
$41.04 M
|
$32.12 M
|
$27.07 M
|
$20.24 M
|
$15.41 M
|
$11.18 M
|
$8.86 M
|
| Cost of Revenue |
$29.40 M |
$29.53 M |
$23.63 M |
$21.47 M |
$16.88 M |
$14.27 M |
$10.55 M |
$9.70 M |
$8.69 M |
$7.63 M |
| Gross Profit |
$20.75 M |
$24.34 M |
$25.48 M |
$19.57 M |
$15.24 M |
$12.80 M |
$9.69 M |
$5.71 M |
$2.50 M |
$1.23 M |
| Gross Profit Ratio |
0.41 |
0.45 |
0.52 |
0.48 |
0.47 |
0.47 |
0.48 |
0.37 |
0.22 |
0.14 |
| Research and Development
Expenses |
$9.54 M
|
$11.55 M
|
$9.37 M
|
$7.20 M
|
$5.85 M
|
$4.80 M
|
$4.40 M
|
$4.29 M
|
$4.19 M
|
$4.85 M
|
| General & Administrative
Expenses |
$11.07 M
|
$10.24 M
|
$9.12 M
|
$6.51 M
|
$6.61 M
|
$4.68 M
|
$4.07 M
|
$4.96 M
|
$5.17 M
|
$5.34 M
|
| Selling & Marketing
Expenses |
$7.06 M
|
$7.00 M
|
$6.38 M
|
$5.52 M
|
$4.24 M
|
$3.06 M
|
$2.57 M
|
$3.26 M
|
$3.45 M
|
$4.28 M
|
| Selling, General &
Administrative Expenses |
$18.13 M
|
$17.24 M
|
$15.50 M
|
$12.03 M
|
$10.86 M
|
$7.73 M
|
$6.64 M
|
$8.22 M
|
$8.62 M
|
$9.62 M
|
| Other Expenses |
$435,000.00 |
-$11,000.00 |
-$24,000.00 |
$71,000.00 |
-$42,000.00 |
-$39,000.00 |
-$88,000.00 |
-$56,000.00 |
-$38,000.00 |
$225,000.00 |
| Operating Expenses |
$28.11 M |
$28.79 M |
$24.87 M |
$19.23 M |
$16.71 M |
$12.53 M |
$11.04 M |
$12.52 M |
$12.81 M |
$14.47 M |
| Cost And Expenses |
$57.51 M |
$58.32 M |
$48.50 M |
$40.70 M |
$33.59 M |
$26.80 M |
$21.60 M |
$22.22 M |
$21.50 M |
$22.10 M |
| Interest Income |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
| Interest Expense |
$0.00 |
$0.00 |
$24,000.00 |
$0.00 |
$0.00 |
$39,000.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
| Depreciation &
Amortization |
$1.87 M
|
$3.20 M
|
$2.41 M
|
$1.58 M
|
$1.23 M
|
$606,000.00
|
$360,000.00
|
$168,000.00
|
$156,000.00
|
$214,000.00
|
| EBITDA |
-$5.05 M
|
-$2.07 M
|
$2.23 M
|
$366,000.00
|
-$735,000.00
|
$876,000.00
|
-$994,000.00
|
-$6.64 M
|
-$10.16 M
|
-$13.02 M
|
| EBITDA Ratio |
-0.1 |
-0.03 |
0.05 |
0.04 |
-0.01 |
0.03 |
-0.05 |
-0.43 |
-0.91 |
-1.47 |
| Operating Income Ratio
|
-0.15
|
-0.08
|
0.01
|
0.01
|
-0.05
|
0.01
|
-0.07
|
-0.44
|
-0.92
|
-1.49
|
| Total Other
Income/Expenses Net |
$48,000.00
|
-$11,000.00
|
-$24,000.00
|
$71,000.00
|
-$495,000.00
|
-$39,000.00
|
-$89,000.00
|
-$56,000.00
|
-$38,000.00
|
$225,000.00
|
| Income Before Tax |
-$7.31 M |
-$5.27 M |
$583,000.00 |
$409,000.00 |
-$1.85 M |
$231,000.00 |
-$1.44 M |
-$6.87 M |
-$10.35 M |
-$13.01 M |
| Income Before Tax Ratio
|
-0.15
|
-0.1
|
0.01
|
0.01
|
-0.06
|
0.01
|
-0.07
|
-0.45
|
-0.93
|
-1.47
|
| Income Tax Expense |
-$32,000.00 |
$68,000.00 |
$35,000.00 |
$75,000.00 |
$130,000.00 |
$103,000.00 |
$63,000.00 |
$19,000.00 |
$92,000.00 |
$127,000.00 |
| Net Income |
-$7.28 M |
-$5.34 M |
$548,000.00 |
$362,000.00 |
-$1.98 M |
$128,000.00 |
-$1.51 M |
-$6.88 M |
-$10.45 M |
-$13.14 M |
| Net Income Ratio |
-0.15 |
-0.1 |
0.01 |
0.01 |
-0.06 |
0 |
-0.07 |
-0.45 |
-0.93 |
-1.48 |
| EPS |
-0.54 |
-0.39 |
0.0415 |
0.0276 |
-0.17 |
0.0113 |
-0.14 |
-0.64 |
-1.2 |
-1.51 |
| EPS Diluted |
-0.54 |
-0.39 |
0.0387 |
0.0248 |
-0.17 |
0.0091 |
-0.14 |
-0.63 |
-1.2 |
-1.51 |
| Weighted Average Shares
Out |
$13.55 M
|
$13.54 M
|
$13.20 M
|
$13.14 M
|
$11.84 M
|
$11.34 M
|
$10.99 M
|
$10.68 M
|
$8.70 M
|
$8.70 M
|
| Weighted Average Shares
Out Diluted |
$13.55 M
|
$13.54 M
|
$14.16 M
|
$14.57 M
|
$11.84 M
|
$14.10 M
|
$11.00 M
|
$10.98 M
|
$8.70 M
|
$8.70 M
|
| Link |
|
|
|
|
|
|
|
|
|
|
